GoodRx to Restate First-Half 2026 Financials Overstating Revenue
GoodRx Holdings plans to restate its first-half 2026 financials because revenue was understated.
Related stories
Apple CFO Sees Memory Purchase Pricing Continuing to Rise
Apple’s CFO said memory purchase pricing is continuing to increase.
L impact | EQUITY | Nov 02, 2026, 10:40 PM UTC
Apple CFO Says Memory Purchase Prices Continue to Rise
Apple's CFO said on a conference call that pricing for memory purchases continues to increase.
M impact | EQUITY | Nov 02, 2026, 10:40 PM UTC
Calix Q3 Revenue Rises, Issues Q4 Guidance
Calix reported higher Q3 revenue and issued Q4 guidance.
M impact | EQUITY | Nov 02, 2026, 10:40 PM UTC
Ero Copper Reports Q3 Production of 18,345 Tonnes in Concentrate
Ero Copper reported consolidated Q3 copper production of 18,345 tonnes in concentrate and C1 cash costs of $2.51 per pound.
M impact | EQUITY | Nov 02, 2026, 10:39 PM UTC
Apple Extends Extended-Hours Drop, Down 3.96% at $324.92
Apple shares were last down 3.96% at $324.92 in extended trading.
M impact | EQUITY | Nov 02, 2026, 10:38 PM UTC
Boise Cascade Reports Higher Q3 Earnings and Sales
Boise Cascade reported that Q3 earnings and sales rose.
M impact | EQUITY | Nov 02, 2026, 10:38 PM UTC